Success Metrics

Clinical Success Rate
16.7%

Based on 1 completed trials

Completion Rate
17%(1/6)
Active Trials
0(0%)
Results Posted
500%(5 trials)
Terminated
5(42%)

Phase Distribution

Ph early_phase_1
1
8%
Ph phase_3
1
8%
Ph phase_1
5
42%
Ph phase_2
5
42%

Phase Distribution

6

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution12 total trials
Early Phase 1First-in-human
1(8.3%)
Phase 1Safety & dosage
5(41.7%)
Phase 2Efficacy & side effects
5(41.7%)
Phase 3Large-scale testing
1(8.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

11.1%

1 of 9 finished

Non-Completion Rate

88.9%

8 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Active(2)
Completed(1)
Terminated(8)
Other(1)

Detailed Status

Terminated5
Withdrawn3
Enrolling by invitation2
Completed1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
16.7%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (8.3%)
Phase 15 (41.7%)
Phase 25 (41.7%)
Phase 31 (8.3%)

Trials by Status

withdrawn325%
enrolling_by_invitation217%
completed18%
unknown18%
terminated542%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_2

Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

NCT04233567
terminatedphase_1

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

NCT04504331
enrolling_by_invitationphase_2

Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia

NCT07393373
enrolling_by_invitationphase_2

Extension Study of Infigratinib in Children With Achondroplasia (ACH)

NCT05145010
terminatedearly_phase_1

Infigratinib in Recurrent High-Grade Glioma Patients

NCT04424966
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT04233567Phase 2

Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

Completed
NCT04504331Phase 1

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Terminated
NCT07393373Phase 2

Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia

Enrolling By Invitation
NCT05145010Phase 2

Extension Study of Infigratinib in Children With Achondroplasia (ACH)

Enrolling By Invitation
NCT04424966Early Phase 1

Infigratinib in Recurrent High-Grade Glioma Patients

Terminated
NCT04228042Phase 1

Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer

Terminated
NCT06206278Phase 2

Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

Terminated
NCT04197986Phase 3

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

Terminated
NCT05510427Phase 1

Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

Withdrawn
NCT05222165Phase 1

Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

Withdrawn
NCT04972253Phase 1

Phase I BLASST-3 Trial

Withdrawn
NCT05019794Phase 2

Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations

Unknown

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12